Comparative Pharmacology
Head-to-head clinical analysis: BISOPROLOL FUMARATE versus CARTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISOPROLOL FUMARATE versus CARTROL.
BISOPROLOL FUMARATE vs CARTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and renin release from kidneys.
CARTROL is a beta-1 selective adrenergic receptor antagonist. It inhibits the effects of catecholamines on beta-1 receptors in the heart, reducing heart rate, myocardial contractility, and blood pressure.
Adults: Initial dose 2.5-5 mg orally once daily, titrate to 10 mg once daily; maximum 20 mg once daily.
Adults: 2.5 mg orally twice daily, titrated up to maximum 10 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours (mean 11 hours), allowing once-daily dosing. Half-life may be prolonged in renal impairment (creatinine clearance <40 mL/min) and in elderly patients.
Terminal elimination half-life is 6–8 hours in normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 50% excreted unchanged in urine; remainder metabolized in liver to inactive metabolites, then renally excreted. Fecal excretion is negligible (<2%). Total renal clearance accounts for ~60-70% of elimination.
Primarily renal excretion (approx. 70% unchanged drug), with 20% biliary/fecal, and 10% metabolism to inactive metabolites.
Category C
Category C
Beta-Blocker
Beta-Blocker